Skip to main content
. 2021 Apr 8;11:7721. doi: 10.1038/s41598-021-87023-2

Table 2.

Table detailing patients exiting the study early, with reason for withdrawal, study day of withdrawal, and treatment group.

Patient Reason for withdrawal Day (period) of withdrawal Treatment group
LAS-11* AE—neurological Day 1 (T1) 2 (RR)
LAS-23 Withdrawal of owner consent Day 19 (T1/T2) 2 (RR)
LAS-26* AE—gastrointestinal—emesis Day 4 (T1) 1 (PP)
LAS-28 AE—gastrointestinal—emesis Day 23 (T2) 2 (RR)
LAS-37* AE—gastrointestinal—emesis Day 11 (T1) 2 (RR)
LAS-38* AE—gastrointestinal—emesis Day 15 (T1) 1 (PP)
LAS-40 AE—integumentary Day 25 (T2) 3 (RP)
LAS-63 AE—gastrointestinal—emesis Day 22 (T2) 1 (PP)
LAS-86 AE—gastrointestinal—emesis Day 16 (T1) 3 (RP)
LAS-87 Recurrence of behavioral disorder—defecation Day 22 (T2) 2 (RR)

LAS patient identification code corresponding to patients enrolled at North Carolina State University, AE adverse event, T1 treatment period 1, T2 treatment period 2, P placebo, R robenacoxib.

*Excluded from the PP analysis due to significant deficiencies in dosing.